The strong beat and raised guidance suggest accelerating organic growth and margin expansion. Consider building or adding to long positions; monitor the company's ability to sustain Pharmacy Solutions growth and integrate the Amedysis/LHC acquisition. The reduced leverage (2.27x) and strong cash flow provide financial flexibility.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 1 $52.58entry
- T+1 · 7mo ago +1.83%α +2.17% · $53.54
- T+5 · 6mo ago +0.68%α −1.66% · $52.94
- T+20 · 6mo ago +14.07%α +8.79% · $59.98
- T+60 · 4mo ago +37.81%α +34.74% · $72.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BrightSpring Health Services reported Q1 2026 revenue of $3,614M (beat consensus of $3,390M by 6.6%) and GAAP diluted EPS from continuing ops of $0.34 (beat consensus of $0.31 by 9.7%). The company raised full-year 2026 guidance for both revenue and Adjusted EBITDA, signaling strong operational momentum. Net income from continuing ops surged to $74M from $9M a year ago, while Adjusted EBITDA grew 44.8% to $190M.
Key Financial Metrics
Key Facts
- Revenue $3,614M, +25.6% YoY, vs consensus $3.39B
- GAAP diluted EPS from continuing ops $0.34, vs consensus $0.31
- Adjusted EBITDA $190M, +44.8% YoY
- FY2026 guidance raised: revenue $14.725B-$15.225B, Adjusted EBITDA $795M-$825M
- Closed Community Living divestiture, generated $810.9M in proceeds
- Repurchased $60M of common stock in March 2026
Financial Impact
Q1 revenue beat by ~$224M (+6.6% vs consensus); EPS beat by $0.03 (+9.7%); full-year guidance raised by ~$700M at midpoint
Risk Factors
- Integration of Amedysis/LHC acquisition may face challenges
- Leverage remains elevated at 2.27x despite reduction
- Dependence on government reimbursement (Medicare/Medicaid) and pharmacy pricing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3285767 |
Track record
24 reports on BTSG
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +45.59% at T+60 after the Feb 27, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $71.36 Now $71.37 +0.01% settles Feb 12
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $67.15 Now $71.37 +6.28% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $65.86 Now $71.37 +8.37% settles Feb 3
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $66.89 Now $71.37 +6.70% settles Jan 28
- Oct 30, 202617d ago 8-K Bullish 6/10 No price data
- Oct 30, 202617d ago Press Release Neutral 5/10 Entry $66.89 Now $71.37 +6.70% settles Jan 28
- Oct 20, 202627d ago Institutional Cluster Neutral 3/10 Entry $62.36 Now $71.37 +14.45% settles Jan 19
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $57.26 Now $71.37 +24.64% settles Dec 28
- Aug 6, 202614w ago Institutional Cluster Bullish 6/10 Entry $60.60 to $66.89 Now $71.37 +17.77% ▲ +10.38% +12.05% vs SPY
- Jul 31, 202615w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers